Tags

Type your tag names separated by a space and hit enter

Use of immunoglobulin G avidity assays for differentiation of primary from previous infections with West Nile virus.
J Clin Microbiol. 2005 Dec; 43(12):5873-5.JC

Abstract

Since its introduction in 1999, West Nile virus (WNV) infections have spread rapidly across the North American continent. Diagnosis of acute WNV infection by detection of WNV-specific immunoglobulin M (IgM) is complicated by the persistence of detectable IgM for more than 1 year in some patients. IgG antibody avidity testing was assessed as a supplemental assay in the diagnosis of current infections. Three groups of serum samples were assayed in parallel by two different IgG avidity test systems (indirect immunofluorescence test [IIFT] and prototype enzyme-linked immunosorbent assay [ELISA]; EUROIMMUN, Luebeck, Germany). Group I (40 sera taken between 2 and 9 days after the onset of influenza-like symptoms) and group II (40 sera taken between 10 and 43 days after onset) were acute and convalescent specimens from patients with a positive anti-WNV IgM test (ELISA; Focus Diagnostics, Cypress, CA). Group III consisted of 43 patient sera collected between 6 and 12 months after infection. IgG antibodies specific for WNV were detected in 38% (ELISA) and 50% (IIFT) of group I sera, in 90% (ELISA and IIFT) of group II sera, and in 100% (ELISA and IIFT) of group III sera. Low-avidity IgG antibodies were demonstrated in 86% (ELISA) and 95% (IIFT) of IgG-positive patient samples taken between 2 and 43 days after the onset of symptoms (groups I and II). High-avidity IgG antibodies were detected in 100% of group III sera obtained 6 months or more after the onset of symptoms (ELISA and IIFT). IgG avidity tests for WNV infections are rapid and simple to perform. The determination of IgG avidity provides additional diagnostic certainty in differentiating between recently acquired and previous infections with WNV.

Links

PMC Free PDF

Authors+Show Affiliations

Levett PN
Provincial Laboratory, Saskatchewan Health, 3211 Albert Street, Regina, Saskatchewan S4S 5W6, Canada. plevett@health.gov.sk.ca
Sonnenberg K
No affiliation info available
Sidaway F
No affiliation info available
Shead S
No affiliation info available
Niedrig M
No affiliation info available
Steinhagen K
No affiliation info available
Horsman GB
No affiliation info available
Drebot MA
No affiliation info available

MeSH

Antibodies, ViralAntibody AffinityAntibody SpecificityEnzyme-Linked Immunosorbent AssayFluorescent Antibody Technique, IndirectHumansImmunoglobulin GImmunoglobulin MRecurrenceWest Nile FeverWest Nile virus

Pub Type(s)

Evaluation Study
Journal Article

Language

eng

PubMed ID

16333069

Citation

Levett, P N., et al. "Use of Immunoglobulin G Avidity Assays for Differentiation of Primary From Previous Infections With West Nile Virus." Journal of Clinical Microbiology, vol. 43, no. 12, 2005, pp. 5873-5.
Levett PN, Sonnenberg K, Sidaway F, et al. Use of immunoglobulin G avidity assays for differentiation of primary from previous infections with West Nile virus. J Clin Microbiol. 2005;43(12):5873-5.
Levett, P. N., Sonnenberg, K., Sidaway, F., Shead, S., Niedrig, M., Steinhagen, K., Horsman, G. B., & Drebot, M. A. (2005). Use of immunoglobulin G avidity assays for differentiation of primary from previous infections with West Nile virus. Journal of Clinical Microbiology, 43(12), 5873-5.
Levett PN, et al. Use of Immunoglobulin G Avidity Assays for Differentiation of Primary From Previous Infections With West Nile Virus. J Clin Microbiol. 2005;43(12):5873-5. PubMed PMID: 16333069.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Use of immunoglobulin G avidity assays for differentiation of primary from previous infections with West Nile virus. AU - Levett,P N, AU - Sonnenberg,K, AU - Sidaway,F, AU - Shead,S, AU - Niedrig,M, AU - Steinhagen,K, AU - Horsman,G B, AU - Drebot,M A, PY - 2005/12/8/pubmed PY - 2006/1/20/medline PY - 2005/12/8/entrez SP - 5873 EP - 5 JF - Journal of clinical microbiology JO - J Clin Microbiol VL - 43 IS - 12 N2 - Since its introduction in 1999, West Nile virus (WNV) infections have spread rapidly across the North American continent. Diagnosis of acute WNV infection by detection of WNV-specific immunoglobulin M (IgM) is complicated by the persistence of detectable IgM for more than 1 year in some patients. IgG antibody avidity testing was assessed as a supplemental assay in the diagnosis of current infections. Three groups of serum samples were assayed in parallel by two different IgG avidity test systems (indirect immunofluorescence test [IIFT] and prototype enzyme-linked immunosorbent assay [ELISA]; EUROIMMUN, Luebeck, Germany). Group I (40 sera taken between 2 and 9 days after the onset of influenza-like symptoms) and group II (40 sera taken between 10 and 43 days after onset) were acute and convalescent specimens from patients with a positive anti-WNV IgM test (ELISA; Focus Diagnostics, Cypress, CA). Group III consisted of 43 patient sera collected between 6 and 12 months after infection. IgG antibodies specific for WNV were detected in 38% (ELISA) and 50% (IIFT) of group I sera, in 90% (ELISA and IIFT) of group II sera, and in 100% (ELISA and IIFT) of group III sera. Low-avidity IgG antibodies were demonstrated in 86% (ELISA) and 95% (IIFT) of IgG-positive patient samples taken between 2 and 43 days after the onset of symptoms (groups I and II). High-avidity IgG antibodies were detected in 100% of group III sera obtained 6 months or more after the onset of symptoms (ELISA and IIFT). IgG avidity tests for WNV infections are rapid and simple to perform. The determination of IgG avidity provides additional diagnostic certainty in differentiating between recently acquired and previous infections with WNV. SN - 0095-1137 UR - https://www.unboundmedicine.com/medline/citation/16333069/Use_of_immunoglobulin_G_avidity_assays_for_differentiation_of_primary_from_previous_infections_with_West_Nile_virus_ DB - PRIME DP - Unbound Medicine ER -